Want to see SE:SPRINT full AI Analyst Report?
SPRINT Stock Chart & Stats
kr1.48
-kr0.03(-2.43%)
At close: 4:00 PM EST
kr1.48
-kr0.03(-2.43%)
Day’s Range― - ―
52-Week Rangekr0.50 - kr4.59
Previous CloseN/A
Volume19.16K
Average Volume (3M)560.98K
Market Cap
kr373.53M
Enterprise Valuekr352.77M
Total Cash (Recent Filing)kr108.33M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)4.5
Beta1.50
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.79
Shares Outstanding105,515,540
10 Day Avg. Volume1,502,692
30 Day Avg. Volume560,983
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.14
Price to Sales (P/S)0.81
P/FCF Ratio1.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr80.50M
Bulls Say, Bears Say
Bulls Say
High Profitability MarginsVery high trailing margins indicate the company captures substantial value from each revenue dollar, consistent with asset-light drug discovery and licensing economics. Elevated margins support durable internal funding of preclinical programs, improve partner negotiation leverage, and enhance the resilience of cash conversion over the coming months.
Strong Cash GenerationOperating and free cash flow roughly matching reported profit demonstrates high earnings quality and good cash conversion. Reliable cash generation reduces near-term financing needs, funds discovery activity, and lowers dilution risk, providing a durable funding base for partnerships and milestone-driven investments across quarters.
Conservative Balance SheetZero debt and a materially strengthened equity base materially reduce financial risk and increase strategic flexibility. This conservative structure supports continued R&D investment, helps absorb clinical/preclinical setbacks, and enables more favorable licensing or partnership terms without forcing near-term capital raises.
Bears Say
Recent Revenue SoftnessAn ~8.4% TTM revenue decline signals weakening top-line momentum which can erode sustainability of current margin and cash levels. For a company dependent on licensing and milestone recognition, declining revenues may reflect fewer or smaller deals, making near-term cash flow and partner-driven upside less predictable.
Historical Volatility In ResultsPast years of losses and negative cash flow (e.g., 2024, 2022) and swings in equity/ROE indicate earnings and cash generation are not yet consistently durable. This historical volatility complicates forecasting, raises execution risk, and can impair long-term partner confidence and planning when advancing programs toward milestones.
Revenue Reliance On PartnershipsRevenue is highly dependent on securing partnership and licensing deals, making income lumpy and contingent on external counterparties. Failure to close deals or delayed milestone recognition can produce extended revenue gaps, increasing funding pressure and execution risk for advancing programs over multi-quarter horizons.
SPRINT FAQ
What was Sprint Bioscience AB’s price range in the past 12 months?
Sprint Bioscience AB lowest stock price was kr0.50 and its highest was kr4.59 in the past 12 months.
What is Sprint Bioscience AB’s market cap?
Sprint Bioscience AB’s market cap is kr373.53M.
When is Sprint Bioscience AB’s upcoming earnings report date?
Sprint Bioscience AB’s upcoming earnings report date is Aug 26, 2026 which is in 35 days.
How were Sprint Bioscience AB’s earnings last quarter?
Sprint Bioscience AB released its earnings results on May 13, 2026. The company reported -kr0.122 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.122.
Is Sprint Bioscience AB overvalued?
According to Wall Street analysts Sprint Bioscience AB’s price is currently Overvalued.
Does Sprint Bioscience AB pay dividends?
Sprint Bioscience AB does not currently pay dividends.
What is Sprint Bioscience AB’s EPS estimate?
Sprint Bioscience AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sprint Bioscience AB have?
Sprint Bioscience AB has 105,515,540 shares outstanding.
What happened to Sprint Bioscience AB’s price movement after its last earnings report?
Sprint Bioscience AB reported an EPS of -kr0.122 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.639%.
Which hedge fund is a major shareholder of Sprint Bioscience AB?
Currently, no hedge funds are holding shares in SE:SPRINT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sprint Bioscience AB
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. The company was incorporated in 2009 and is based in Huddinge, Sweden.